InspireMD

InspireMD is a medical device company focused on developing and commercializing stents with a protective mesh technology for vascular disease treatment. The company is listed on NYSE American under the ticker NSPR, with its registered headquarters in Boston, Massachusetts, and R&D activity historically based in Tel Aviv.

InspireMD's central product line is built around MicroNet technology — a tightly woven mesh sleeve that encases a stent and is designed to trap plaque debris during vessel dilation, reducing the risk of embolic stroke. The primary clinical application is carotid artery stenting (CAS), where embolic complications are the dominant procedural risk.

The flagship product is CGuard EPS, a carotid artery stent integrating the MicroNet embolic protection system. CGuard EPS received FDA approval in 2023 following the C-GUARDIANS pivotal clinical trial. The product had also been available in European markets in prior years under CE Mark.

InspireMD operates in the carotid intervention market, where CAS competes primarily against carotid endarterectomy (open surgery) and other stent-based systems. The FDA clearance of CGuard EPS in 2023 was the company's most significant commercial milestone, opening access to the U.S. market.

InspireMD has maintained R&D presence in Tel Aviv. Detailed current information on Israel headcount or the breakdown of functions there is not something I can confirm with sufficient certainty.